Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levagen+ for Acute Menstrual Pain
NCT05810116Phase 4Completed
- Sponsor
- RDC Clinical
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in dysmenorrhea comparing Levagen+ with Placebo (2 arms). Primary endpoint: Change in acute menstrual pain severity, analgesic effect via Numeric Rating Scale (NRS). Started May 2023; status: completed.
02
Drugs
palmitoylethanolamide
03
Conditions
dysmenorrhea
Beyond the preview
Go deeper on NCT05810116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810116.